TY - JOUR
T1 - Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)
AU - Mullens, Wilfried
AU - Dauw, Jeroen
AU - Gustafsson, Finn
AU - Mebazaa, Alexandre
AU - Steffel, Jan
AU - Witte, Klaus K
AU - Delgado, Victoria
AU - Linde, Cecilia
AU - Vernooy, Kevin
AU - Anker, Stefan D
AU - Chioncel, Ovidiu
AU - Milicic, Davor
AU - Hasenfuß, Gerd
AU - Ponikowski, Piotr
AU - von Bardeleben, Ralph Stephan
AU - Koehler, Friedrich
AU - Ruschitzka, Frank
AU - Damman, Kevin
AU - Schwammenthal, Ehud
AU - Testani, Jeffrey M
AU - Zannad, Faiez
AU - Böhm, Michael
AU - Cowie, Martin R
AU - Dickstein, Kenneth
AU - Jaarsma, Tiny
AU - Filippatos, Gerasimos
AU - Volterrani, Maurizio
AU - Thum, Thomas
AU - Adamopoulos, Stamatis
AU - Cohen-Solal, Alain
AU - Moura, Brenda
AU - Rakisheva, Amina
AU - Ristic, Arsen
AU - Bayes-Genis, Antoni
AU - Van Linthout, Sophie
AU - Tocchetti, Carlo Gabriele
AU - Savarese, Gianluigi
AU - Skouri, Hadi
AU - Adamo, Marianna
AU - Amir, Offer
AU - Yilmaz, Mehmet Birhan
AU - Simpson, Maggie
AU - Tokmakova, Mariya
AU - González, Arantxa
AU - Piepoli, Massimo
AU - Seferovic, Petar
AU - Metra, Marco
AU - Coats, Andrew J S
AU - Rosano, Giuseppe M C
N1 - © 2024 European Society of Cardiology.
PY - 2024/2
Y1 - 2024/2
N2 - Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support. For others, more evidence is still needed before large-scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device-provided therapy and also device-guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care.
AB - Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support. For others, more evidence is still needed before large-scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device-provided therapy and also device-guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care.
KW - Cardiac Resynchronization Therapy
KW - Cardiology
KW - Defibrillators, Implantable
KW - Heart Failure/therapy
KW - Humans
KW - Heart failure
KW - Device therapy
UR - http://www.scopus.com/inward/record.url?scp=85183369699&partnerID=8YFLogxK
U2 - 10.1002/ejhf.3150
DO - 10.1002/ejhf.3150
M3 - Review
C2 - 38269474
SN - 1388-9842
VL - 26
SP - 483
EP - 501
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 2
ER -